Published in Infect Immun on July 01, 2000
Cryptococcus neoformans interactions with amoebae suggest an explanation for its virulence and intracellular pathogenic strategy in macrophages. Proc Natl Acad Sci U S A (2001) 3.37
Cyclic AMP-dependent protein kinase controls virulence of the fungal pathogen Cryptococcus neoformans. Mol Cell Biol (2001) 3.11
Replication of Cryptococcus neoformans in macrophages is accompanied by phagosomal permeabilization and accumulation of vesicles containing polysaccharide in the cytoplasm. Proc Natl Acad Sci U S A (2002) 2.68
Vesicular polysaccharide export in Cryptococcus neoformans is a eukaryotic solution to the problem of fungal trans-cell wall transport. Eukaryot Cell (2006) 2.55
A conserved mechanism of TOR-dependent RCK-mediated mRNA degradation regulates autophagy. Nat Cell Biol (2015) 2.21
Human antibodies against a purified glucosylceramide from Cryptococcus neoformans inhibit cell budding and fungal growth. Infect Immun (2000) 2.12
Glucosylceramide synthase is an essential regulator of pathogenicity of Cryptococcus neoformans. J Clin Invest (2006) 2.08
Fungal cell gigantism during mammalian infection. PLoS Pathog (2010) 2.04
Superoxide dismutase influences the virulence of Cryptococcus neoformans by affecting growth within macrophages. Infect Immun (2003) 2.00
The capsule of the fungal pathogen Cryptococcus neoformans. Adv Appl Microbiol (2009) 1.97
Cryptococcus neoformans gene expression during murine macrophage infection. Eukaryot Cell (2005) 1.89
The fatal fungal outbreak on Vancouver Island is characterized by enhanced intracellular parasitism driven by mitochondrial regulation. Proc Natl Acad Sci U S A (2009) 1.84
Membrane vesicle release in bacteria, eukaryotes, and archaea: a conserved yet underappreciated aspect of microbial life. Infect Immun (2012) 1.73
Roles for inositol-phosphoryl ceramide synthase 1 (IPC1) in pathogenesis of C. neoformans. Genes Dev (2001) 1.72
Cytokine signaling regulates the outcome of intracellular macrophage parasitism by Cryptococcus neoformans. Infect Immun (2009) 1.66
Role of extracellular phospholipases and mononuclear phagocytes in dissemination of cryptococcosis in a murine model. Infect Immun (2004) 1.66
The cryptococcal enzyme inositol phosphosphingolipid-phospholipase C confers resistance to the antifungal effects of macrophages and promotes fungal dissemination to the central nervous system. Infect Immun (2006) 1.60
Advances in combating fungal diseases: vaccines on the threshold. Nat Rev Microbiol (2006) 1.58
Cryptococcal interactions with the host immune system. Eukaryot Cell (2010) 1.57
Role of phagocytosis in the virulence of Cryptococcus neoformans. Eukaryot Cell (2004) 1.57
Depletion of alveolar macrophages decreases the dissemination of a glucosylceramide-deficient mutant of Cryptococcus neoformans in immunodeficient mice. Infect Immun (2007) 1.55
Cell-to-cell spread and massive vacuole formation after Cryptococcus neoformans infection of murine macrophages. BMC Immunol (2007) 1.51
Capsule enlargement in Cryptococcus neoformans confers resistance to oxidative stress suggesting a mechanism for intracellular survival. Cell Microbiol (2008) 1.50
Metabolic adaptation in Cryptococcus neoformans during early murine pulmonary infection. Mol Microbiol (2008) 1.49
Cryptococcus neoformans gene expression during experimental cryptococcal meningitis. Eukaryot Cell (2003) 1.49
Elucidating the pathogenesis of spores from the human fungal pathogen Cryptococcus neoformans. Infect Immun (2009) 1.45
PI3K signaling of autophagy is required for starvation tolerance and virulenceof Cryptococcus neoformans. J Clin Invest (2008) 1.45
Cryptococcus neoformans virulence is enhanced after growth in the genetically malleable host Dictyostelium discoideum. Infect Immun (2003) 1.44
Direct cell-to-cell spread of a pathogenic yeast. BMC Immunol (2007) 1.40
Lipid Flippase Subunit Cdc50 Mediates Drug Resistance and Virulence in Cryptococcus neoformans. MBio (2016) 1.40
cAMP signaling in Aspergillus fumigatus is involved in the regulation of the virulence gene pksP and in defense against killing by macrophages. Mol Genet Genomics (2003) 1.38
Phenotypic switching of Cryptococcus neoformans occurs in vivo and influences the outcome of infection. J Clin Invest (2001) 1.38
Cryptococcal urease promotes the accumulation of immature dendritic cells and a non-protective T2 immune response within the lung. Am J Pathol (2009) 1.38
Cryptococcus neoformans {alpha} strains preferentially disseminate to the central nervous system during coinfection. Infect Immun (2005) 1.33
Dynamic nature of host-pathogen interactions in Mycobacterium marinum granulomas. Infect Immun (2001) 1.32
Both Th1 and Th2 cytokines affect the ability of monoclonal antibodies to protect mice against Cryptococcus neoformans. Infect Immun (2001) 1.32
Pheromones stimulate mating and differentiation via paracrine and autocrine signaling in Cryptococcus neoformans. Eukaryot Cell (2002) 1.32
Role of a CUF1/CTR4 copper regulatory axis in the virulence of Cryptococcus neoformans. J Clin Invest (2007) 1.32
The relative susceptibility of mouse strains to pulmonary Cryptococcus neoformans infection is associated with pleiotropic differences in the immune response. Infect Immun (2007) 1.30
Cryptococcus neoformans requires a functional glycolytic pathway for disease but not persistence in the host. MBio (2011) 1.29
Cryptococcus neoformans capsular enlargement and cellular gigantism during Galleria mellonella infection. PLoS One (2011) 1.29
Immunoglobulin G monoclonal antibodies to Cryptococcus neoformans protect mice deficient in complement component C3. Infect Immun (2002) 1.24
The Cryptococcus neoformans catalase gene family and its role in antioxidant defense. Eukaryot Cell (2006) 1.24
Survival defects of Cryptococcus neoformans mutants exposed to human cerebrospinal fluid result in attenuated virulence in an experimental model of meningitis. Infect Immun (2010) 1.22
In vivo role of dendritic cells in a murine model of pulmonary cryptococcosis. Infect Immun (2006) 1.21
Cryptococcus neoformans Rim101 is associated with cell wall remodeling and evasion of the host immune responses. MBio (2013) 1.20
Eca1, a sarcoplasmic/endoplasmic reticulum Ca2+-ATPase, is involved in stress tolerance and virulence in Cryptococcus neoformans. Infect Immun (2007) 1.17
Nonlytic exocytosis of Cryptococcus neoformans from macrophages occurs in vivo and is influenced by phagosomal pH. MBio (2011) 1.15
Adaptation of Cryptococcus neoformans to mammalian hosts: integrated regulation of metabolism and virulence. Eukaryot Cell (2011) 1.14
Chemokine receptor 2-mediated accumulation of fungicidal exudate macrophages in mice that clear cryptococcal lung infection. Am J Pathol (2010) 1.14
Phospholipids trigger Cryptococcus neoformans capsular enlargement during interactions with amoebae and macrophages. PLoS Pathog (2011) 1.11
Melanization of Cryptococcus neoformans affects lung inflammatory responses during cryptococcal infection. Infect Immun (2005) 1.10
Cryptococci at the brain gate: break and enter or use a Trojan horse? J Clin Invest (2010) 1.09
The intracellular life of Cryptococcus neoformans. Annu Rev Pathol (2013) 1.06
Intracellular pathogenic bacteria and fungi--a case of convergent evolution? Nat Rev Microbiol (2008) 1.06
Phenotypic switching in a Cryptococcus neoformans variety gattii strain is associated with changes in virulence and promotes dissemination to the central nervous system. Infect Immun (2006) 1.05
Phagocytosis of Cryptococcus neoformans by, and nonlytic exocytosis from, Acanthamoeba castellanii. Appl Environ Microbiol (2010) 1.04
The Cryptococcus neoformans Rho-GDP dissociation inhibitor mediates intracellular survival and virulence. Infect Immun (2008) 1.03
Antibody-mediated protection in murine Cryptococcus neoformans infection is associated with pleotrophic effects on cytokine and leukocyte responses. Infect Immun (2002) 1.01
SEC14 is a specific requirement for secretion of phospholipase B1 and pathogenicity of Cryptococcus neoformans. Mol Microbiol (2011) 0.99
Intracellular crystal formation as a mechanism of cytotoxicity in murine pulmonary Cryptococcus neoformans infection. Infect Immun (2001) 0.99
The outcome of Cryptococcus neoformans intracellular pathogenesis in human monocytes. BMC Microbiol (2009) 0.98
Enhanced innate immune responsiveness to pulmonary Cryptococcus neoformans infection is associated with resistance to progressive infection. Infect Immun (2008) 0.98
Cell wall targeting of laccase of Cryptococcus neoformans during infection of mice. Infect Immun (2006) 0.97
Automated analysis of cryptococcal macrophage parasitism using GFP-tagged cryptococci. PLoS One (2010) 0.97
Molecular mechanisms of cryptococcal meningitis. Virulence (2012) 0.97
Role of CTR4 in the Virulence of Cryptococcus neoformans. MBio (2012) 0.96
Macrophage autophagy in immunity to Cryptococcus neoformans and Candida albicans. Infect Immun (2012) 0.95
Phenotypic switching in Cryptococcus neoformans. Microbiology (2006) 0.94
Immunosuppression, interleukin-10 synthesis and apoptosis are induced in rats inoculated with Cryptococcus neoformans glucuronoxylomannan. Immunology (2004) 0.94
Hydroxyurea treatment inhibits proliferation of Cryptococcus neoformans in mice. Front Microbiol (2012) 0.93
Molecular basis for immunoglobulin M specificity to epitopes in Cryptococcus neoformans polysaccharide that elicit protective and nonprotective antibodies. Infect Immun (2001) 0.93
Cryptococcus neoformans variants generated by phenotypic switching differ in virulence through effects on macrophage activation. Infect Immun (2010) 0.92
Effects of voriconazole on Cryptococcus neoformans. Antimicrob Agents Chemother (2004) 0.92
Characterization of inositol phospho-sphingolipid-phospholipase C 1 (Isc1) in Cryptococcus neoformans reveals unique biochemical features. FEBS Lett (2011) 0.92
Loss of allergen 1 confers a hypervirulent phenotype that resembles mucoid switch variants of Cryptococcus neoformans. Infect Immun (2008) 0.92
Phenotypic switching in Cryptococcus neoformans contributes to virulence by changing the immunological host response. Infect Immun (2008) 0.90
Capsular Material of Cryptococcus neoformans: Virulence and Much More. Mycopathologia (2012) 0.90
Vesicular Trans-Cell Wall Transport in Fungi: A Mechanism for the Delivery of Virulence-Associated Macromolecules? Lipid Insights (2008) 0.90
Toll-like receptor stimulation increases phagocytosis of Cryptococcus neoformans by microglial cells. J Neuroinflammation (2013) 0.89
Mechanisms of dendritic cell lysosomal killing of Cryptococcus. Sci Rep (2012) 0.89
Binding of glucuronoxylomannan to the CD14 receptor in human A549 alveolar cells induces interleukin-8 production. Clin Vaccine Immunol (2006) 0.89
Transcriptional and proteomic responses to carbon starvation in Paracoccidioides. PLoS Negl Trop Dis (2014) 0.89
Role of host sphingosine kinase 1 in the lung response against Cryptococcosis. Infect Immun (2010) 0.88
Paradoxical roles of alveolar macrophages in the host response to Cryptococcus neoformans. J Infect Chemother (2011) 0.87
Phenotypic switching and its implications for the pathogenesis of Cryptococcus neoformans. FEMS Yeast Res (2006) 0.87
Phenotypic Switching in Fungi. Curr Fungal Infect Rep (2008) 0.87
Antibody action after phagocytosis promotes Cryptococcus neoformans and Cryptococcus gattii macrophage exocytosis with biofilm-like microcolony formation. Cell Microbiol (2008) 0.86
Old Cryptococcus neoformans cells contribute to virulence in chronic cryptococcosis. MBio (2013) 0.85
Murine IgG1 and IgG3 isotype switch variants promote phagocytosis of Cryptococcus neoformans through different receptors. J Immunol (2009) 0.85
Altered immune response differentially enhances susceptibility to Cryptococcus neoformans and Cryptococcus gattii infection in mice expressing the HIV-1 transgene. Infect Immun (2013) 0.85
Role of glucose in the expression of Cryptococcus neoformans antiphagocytic protein 1, App1. Eukaryot Cell (2011) 0.84
Role of sphingosine-1-phosphate (S1P) and S1P receptor 2 in the phagocytosis of Cryptococcus neoformans by alveolar macrophages. Microbiology (2011) 0.84
Rat eosinophils stimulate the expansion of Cryptococcus neoformans-specific CD4(+) and CD8(+) T cells with a T-helper 1 profile. Immunology (2010) 0.84
Morphology and its underlying genetic regulation impact the interaction between Cryptococcus neoformans and its hosts. Med Mycol (2015) 0.83
The unappreciated intracellular lifestyle of Blastomyces dermatitidis. J Immunol (2015) 0.83
Investigation of the basis of virulence in serotype A strains of Cryptococcus neoformans from apparently immunocompetent individuals. Curr Genet (2004) 0.83
Where do they come from and where do they go: candidates for regulating extracellular vesicle formation in fungi. Int J Mol Sci (2013) 0.83
In vitro model of penetration and intracellular growth of Listeria monocytogenes in the human enterocyte-like cell line Caco-2. Infect Immun (1987) 11.24
Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev (1995) 8.81
The granulomatous inflammatory response. A review. Am J Pathol (1976) 4.13
Decreased virulence in stable, acapsular mutants of cryptococcus neoformans. Mycopathologia (1982) 4.05
Factors influencing killing of Cryptococcus neoformans by human leukocytes in vitro. J Infect Dis (1972) 3.75
Differential interaction with endocytic and exocytic pathways distinguish parasitophorous vacuoles of Coxiella burnetii and Chlamydia trachomatis. Infect Immun (1996) 3.67
Cryptococcus neoformans var. grubii: separate varietal status for Cryptococcus neoformans serotype A isolates. J Clin Microbiol (1999) 3.38
Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection. J Infect Dis (1992) 2.98
Ecology, life cycle, and infectious propagule of Cryptococcus neoformans. Lancet (1990) 2.87
Estimation of the prevalence of cryptococcal infection among patients infected with the human immunodeficiency virus in New York City. Clin Infect Dis (1994) 2.87
Epidemiological evidence for dormant Cryptococcus neoformans infection. J Clin Microbiol (1999) 2.78
Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies. Antimicrob Agents Chemother (1998) 2.74
Cell-mediated immunity in Cryptococcosis. Cell Immunol (1974) 2.68
Susceptibility of melanized and nonmelanized Cryptococcus neoformans to nitrogen- and oxygen-derived oxidants. Infect Immun (1994) 2.41
Growth of Cryptococcus neoformans within human macrophages in vitro. Infect Immun (1973) 2.39
Parasitophorous vacuoles of Leishmania amazonensis-infected macrophages maintain an acidic pH. Infect Immun (1990) 2.26
Effect of serum IgG1 to Cryptococcus neoformans glucuronoxylomannan on murine pulmonary infection. J Immunol (1997) 2.25
Cryptococcus neoformans resides in an acidic phagolysosome of human macrophages. Infect Immun (1999) 2.22
Studies on the cellular immunology of acute bacterial infections. Harvey Lect (1953) 2.17
Microevolution of a standard strain of Cryptococcus neoformans resulting in differences in virulence and other phenotypes. Infect Immun (1998) 2.12
Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice. Infect Immun (1994) 2.07
Macrophage-mediated fungistasis in vitro: requirements for intracellular and extracellular cytotoxicity. J Immunol (1986) 2.06
Cryptococcosis (torulosis). Current concepts and therapy. Am J Med (1959) 1.97
IL-5 is required for eosinophil recruitment, crystal deposition, and mononuclear cell recruitment during a pulmonary Cryptococcus neoformans infection in genetically susceptible mice (C57BL/6). J Immunol (1998) 1.93
Early events in initiation of alternative complement pathway activation by the capsule of Cryptococcus neoformans. Infect Immun (1991) 1.90
Histoplasma capsulatum modulates the acidification of phagolysosomes. J Exp Med (1993) 1.82
Down-regulation of the afferent phase of T cell-mediated pulmonary inflammation and immunity by a high melanin-producing strain of Cryptococcus neoformans. J Immunol (1995) 1.80
Phospholipase activity in Cryptococcus neoformans: a new virulence factor? J Infect Dis (1997) 1.72
Paradoxical role of capsule in murine bronchoalveolar macrophage-mediated killing of Cryptococcus neoformans. J Immunol (1989) 1.69
Intracellular fate of Cryptococcus neoformans. Infect Immun (1972) 1.63
Growth inhibition of Cryptococcus neoformans by cultured human monocytes: role of the capsule, opsonins, the culture surface, and cytokines. Infect Immun (1990) 1.62
Melanization of Cryptococcus neoformans in murine infection. Mol Cell Biol (1999) 1.59
Capsular polysaccharide of Cryptococcus neoformans induces proinflammatory cytokine release by human neutrophils. Infect Immun (1996) 1.53
Sites of lipoprotein particles in normal rat hepatocytes. J Cell Biol (1978) 1.48
Antibody-dependent leukocyte killing of Cryptococcus neoformans. J Immunol (1983) 1.47
Opsonic requirements for the uptake of Cryptococcus neoformans by human polymorphonuclear leukocytes and monocytes. J Infect Dis (1982) 1.47
Antibodies to the Cryptococcus neoformans capsular glucuronoxylomannan are ubiquitous in serum from HIV+ and HIV- individuals. Clin Exp Immunol (1995) 1.45
Chloroquine induces human mononuclear phagocytes to inhibit and kill Cryptococcus neoformans by a mechanism independent of iron deprivation. J Clin Invest (1997) 1.43
Extracellular proteinase activity of Cryptococcus neoformans. Clin Diagn Lab Immunol (1996) 1.36
Binding of host collectins to the pathogenic yeast Cryptococcus neoformans: human surfactant protein D acts as an agglutinin for acapsular yeast cells. Infect Immun (1995) 1.32
Antibody response to Cryptococcus neoformans proteins in rodents and humans. Infect Immun (1999) 1.26
Cryptococcus neoformans survive and replicate in human microglia. Lab Invest (1995) 1.26
Growth inhibition of Cryptococcus neoformans by human alveolar macrophages. Am Rev Respir Dis (1987) 1.20
Formation of histiocyte rings in response to Cryptococcus neoformans infection. J Reticuloendothel Soc (1965) 1.16
Inorganic trimetaphosphatase as a histochemical marker for lysosomes in light and electron microscopy. J Histochem Cytochem (1977) 1.16
Role for C5 and neutrophils in the pulmonary intravascular clearance of circulating Cryptococcus neoformans. Am J Respir Cell Mol Biol (1993) 1.14
Primary cutaneous cryptococcosis: review and morphologic study. Am J Clin Pathol (1972) 1.14
Effect of antibody to capsular polysaccharide on eosinophilic pneumonia in murine infection with Cryptococcus neoformans. J Infect Dis (1998) 1.08
Eosinophil-Cryptococcus neoformans interactions in vivo and in vitro. Infect Immun (1997) 1.08
Characterization of the biological activity of Cryptococcus infections in surgical pathology. The Budding Index and Carminophilic Index. Ann Clin Lab Sci (1988) 0.98
Cryptococcal immunity and immunostimulation. Adv Exp Med Biol (1992) 0.95
An ultrastructural examination of the interaction between macrophages and Cryptococcus neoformans. J Pathol (1978) 0.90
Ultrastructural study of hepatic granulomas induced by Cryptococcus neoformans by quick-freezing and deep-etching method. Virchows Arch B Cell Pathol Incl Mol Pathol (1993) 0.88
Cytochemistry of acid mucosubstance and acid phosphatase in Cryptococcus neoformans. Can J Microbiol (1974) 0.86
Acid phosphatase release from intact phagocytic cells surrounding a large-sized parasite. Proc Soc Exp Biol Med (1971) 0.85
Intravascular granuloma induced by intravenous inoculation of Cryptococcus neoformans. Mycopathologia (1996) 0.85
Localized cutaneous cryptococcosis successfully treated with ketoconazole. J Am Acad Dermatol (1987) 0.82
Ultrastructural localization of acid phosphatase in the yeast Cryptococcus neoformans. Experientia (1970) 0.82
Ultrastructure of Cryptococcus neoformans. Acta Derm Venereol (1982) 0.80
Differential binding of acapsulate and encapsulated strains of Cryptococcus neoformans to human neutrophils. J Med Vet Mycol (1993) 0.80
Mitochondrial abnormalities in Alzheimer's disease. J Neurosci (2001) 4.39
Pathogenesis of tuberculosis: interaction of Mycobacterium tuberculosis with macrophages. Infect Immun (1993) 3.80
Urease as a virulence factor in experimental cryptococcosis. Infect Immun (2000) 3.53
Cryptococcus neoformans melanin and virulence: mechanism of action. Infect Immun (1995) 3.43
Cryptococcus neoformans var. grubii: separate varietal status for Cryptococcus neoformans serotype A isolates. J Clin Microbiol (1999) 3.38
Cryptococcus neoformans interactions with amoebae suggest an explanation for its virulence and intracellular pathogenic strategy in macrophages. Proc Natl Acad Sci U S A (2001) 3.37
Intracellular parasitism of macrophages by Cryptococcus neoformans. Trends Microbiol (2001) 3.34
Persistence of initial infection in recurrent Cryptococcus neoformans meningitis. Lancet (1993) 3.34
Protective murine monoclonal antibodies to Cryptococcus neoformans. Infect Immun (1992) 3.21
Extracellular phospholipase activity is a virulence factor for Cryptococcus neoformans. Mol Microbiol (2001) 3.02
Estimation of the prevalence of cryptococcal infection among patients infected with the human immunodeficiency virus in New York City. Clin Infect Dis (1994) 2.87
Restriction fragment length polymorphism analysis of Cryptococcus neoformans isolates from environmental (pigeon excreta) and clinical sources in New York City. J Clin Microbiol (1994) 2.43
Susceptibility of melanized and nonmelanized Cryptococcus neoformans to nitrogen- and oxygen-derived oxidants. Infect Immun (1994) 2.41
Cytotoxicity for lung epithelial cells is a virulence-associated phenotype of Mycobacterium tuberculosis. Infect Immun (1995) 2.41
Serologic evidence for Cryptococcus neoformans infection in early childhood. Pediatrics (2001) 2.40
Conformational change as one of the earliest alterations of tau in Alzheimer's disease. Neurobiol Aging (2000) 2.40
Effect of serum IgG1 to Cryptococcus neoformans glucuronoxylomannan on murine pulmonary infection. J Immunol (1997) 2.25
Molecular epidemiology of Cryptococcus neoformans in Brazil and the United States: evidence for both local genetic differences and a global clonal population structure. J Clin Microbiol (1997) 2.19
Melanin, melanin "ghosts," and melanin composition in Cryptococcus neoformans. Infect Immun (1996) 2.15
A mAb recognizing a surface antigen of Mycobacterium tuberculosis enhances host survival. Proc Natl Acad Sci U S A (1998) 2.13
Microevolution of a standard strain of Cryptococcus neoformans resulting in differences in virulence and other phenotypes. Infect Immun (1998) 2.12
Protective and nonprotective monoclonal antibodies to Cryptococcus neoformans originating from one B cell. J Exp Med (1995) 2.11
Molecular characterization of the humoral responses to Cryptococcus neoformans infection and glucuronoxylomannan-tetanus toxoid conjugate immunization. J Exp Med (1993) 2.09
Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophages. Infect Immun (1995) 2.09
Dynamic changes in the morphology of Cryptococcus neoformans during murine pulmonary infection. Microbiology (2001) 2.08
Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice. Infect Immun (1994) 2.07
Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B. Antimicrob Agents Chemother (1994) 2.00
Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro. Antimicrob Agents Chemother (1997) 1.89
Antibody-mediated protection in mice with lethal intracerebral Cryptococcus neoformans infection. Proc Natl Acad Sci U S A (1993) 1.86
Pathogenesis of pulmonary Cryptococcus neoformans infection in the rat. Infect Immun (1994) 1.83
Serum therapy for tuberculosis revisited: reappraisal of the role of antibody-mediated immunity against Mycobacterium tuberculosis. Clin Microbiol Rev (1998) 1.82
Tissue localization of Cryptococcus neoformans glucuronoxylomannan in the presence and absence of specific antibody. Infect Immun (1995) 1.79
Synthesis of polymerized melanin by Cryptococcus neoformans in infected rodents. Infect Immun (2000) 1.79
Monoclonal antibodies to Alzheimer neurofibrillary tangles. 2. Demonstration of a common antigenic determinant between ANT and neurofibrillary degeneration in progressive supranuclear palsy. Am J Pathol (1985) 1.77
Monoclonal antibodies to surface antigens of Mycobacterium tuberculosis and their use in a modified enzyme-linked immunosorbent spot assay for detection of mycobacteria. J Clin Microbiol (1996) 1.76
Studies of in vitro infection by Trypanosoma cruzi. I. Ultrastructural studies on the invasion of macrophages and L-cells. Am J Trop Med Hyg (1975) 1.74
T cells cooperate with passive antibody to modify Cryptococcus neoformans infection in mice. Proc Natl Acad Sci U S A (1997) 1.72
Roles for inositol-phosphoryl ceramide synthase 1 (IPC1) in pathogenesis of C. neoformans. Genes Dev (2001) 1.72
Pathology of cryptococcal meningoencephalitis: analysis of 27 patients with pathogenetic implications. Hum Pathol (1996) 1.71
Variation in the structure of glucuronoxylomannan in isolates from patients with recurrent cryptococcal meningitis. Infect Immun (1995) 1.70
Cellular charge of Cryptococcus neoformans: contributions from the capsular polysaccharide, melanin, and monoclonal antibody binding. Infect Immun (1997) 1.69
Hippocampal degeneration differentiates diffuse Lewy body disease (DLBD) from Alzheimer's disease: light and electron microscopic immunocytochemistry of CA2-3 neurites specific to DLBD. Neurology (1991) 1.69
Isotype switching from IgG3 to IgG1 converts a nonprotective murine antibody to Cryptococcus neoformans into a protective antibody. J Immunol (1995) 1.67
Enhancement of HIV-1 infection by the capsular polysaccharide of Cryptococcus neoformans. Lancet (1992) 1.67
Decreased susceptibility of melanized Cryptococcus neoformans to UV light. Appl Environ Microbiol (1994) 1.65
Laccase of Cryptococcus neoformans is a cell wall-associated virulence factor. Infect Immun (2001) 1.64
Organ-dependent variation of capsule thickness in Cryptococcus neoformans during experimental murine infection. Infect Immun (1998) 1.63
cAMP-dependent protein kinase phosphorylations on tau in Alzheimer's disease. J Neurosci (1999) 1.63
Phenotypic switching in Cryptococcus neoformans results in changes in cellular morphology and glucuronoxylomannan structure. Infect Immun (1999) 1.60
Epitope location in the Cryptococcus neoformans capsule is a determinant of antibody efficacy. J Exp Med (1997) 1.60
Melanization of Cryptococcus neoformans in murine infection. Mol Cell Biol (1999) 1.59
Phenotypic switching in the human pathogenic fungus Cryptococcus neoformans is associated with changes in virulence and pulmonary inflammatory response in rodents. Proc Natl Acad Sci U S A (1998) 1.58
Radiological studies reveal radial differences in the architecture of the polysaccharide capsule of Cryptococcus neoformans. Eukaryot Cell (2005) 1.58
Another look at lead inclusion bodies. Am J Pathol (1968) 1.56
Karyotype instability in Cryptococcus neoformans infection. J Clin Microbiol (1996) 1.53
Growth of Cryptococcus neoformans in presence of L-dopa decreases its susceptibility to amphotericin B. Antimicrob Agents Chemother (1994) 1.53
Molecular epidemiology of clinical Cryptococcus neoformans strains from India. J Clin Microbiol (2005) 1.53
Diffuse Lewy body disease: light and electron microscopic immunocytochemistry of senile plaques. Acta Neuropathol (1989) 1.52
J774 murine macrophage-like cell interactions with Cryptococcus neoformans in the presence and absence of opsonins. J Infect Dis (1996) 1.51
Ubiquitin immunoreactive structures in normal human brains. Distribution and developmental aspects. Lab Invest (1990) 1.51
Melanisation of Cryptococcus neoformans in human brain tissue. Lancet (2000) 1.50
Serum therapy for Cryptococcal meningitis. Clin Infect Dis (1995) 1.50
The M cell as a portal of entry to the lung for the bacterial pathogen Mycobacterium tuberculosis. Immunity (1999) 1.50
Melanin as a potential cryptococcal defence against microbicidal proteins. Med Mycol (1999) 1.48
Mouse-human immunoglobulin G1 chimeric antibodies with activities against Cryptococcus neoformans. Antimicrob Agents Chemother (1994) 1.48
Trypanosoma cruzi: infection of normal and activated mouse macrophages. Exp Parasitol (1977) 1.44
Resistance of Trypanosoma cruzi to killing by macrophages. Nature (1975) 1.43
The antibody response to fungal melanin in mice. J Immunol (1998) 1.42
Immunoglobulin M efficacy against Cryptococcus neoformans: mechanism, dose dependence, and prozone-like effects in passive protection experiments. J Immunol (2001) 1.42
Isolation and serological analyses of fungal melanins. J Immunol Methods (2000) 1.41
Fibrous long-spacing collagen in bacillary angiomatosis. Ultrastruct Pathol (1998) 1.41
Effects of protein calorie malnutrition on tuberculosis in mice. Proc Natl Acad Sci U S A (1996) 1.39
Biological correlates of capsular (quellung) reactions of Cryptococcus neoformans. J Immunol (2000) 1.39
Phenotypic switching of Cryptococcus neoformans occurs in vivo and influences the outcome of infection. J Clin Invest (2001) 1.38
The different binding patterns of two immunoglobulin M monoclonal antibodies to Cryptococcus neoformans serotype A and D strains correlate with serotype classification and differences in functional assays. Clin Diagn Lab Immunol (1998) 1.37
Prevalence of Cryptococcus neoformans var. neoformans (Serotype D) and Cryptococcus neoformans var. grubii (Serotype A) isolates in New York City. J Clin Microbiol (2000) 1.36
Extracellular proteinase activity of Cryptococcus neoformans. Clin Diagn Lab Immunol (1996) 1.36
Both Th1 and Th2 cytokines affect the ability of monoclonal antibodies to protect mice against Cryptococcus neoformans. Infect Immun (2001) 1.32
Detection of melanin-like pigments in the dimorphic fungal pathogen Paracoccidioides brasiliensis in vitro and during infection. Infect Immun (2001) 1.31
Effect of immune mechanisms on the pharmacokinetics and organ distribution of cryptococcal polysaccharide. J Infect Dis (1998) 1.30
Serial isolates of Cryptococcus neoformans from patients with AIDS differ in virulence for mice. J Infect Dis (1998) 1.30
Ubiquitin immunoelectron microscopy of dystrophic neurites in cerebellar senile plaques of Alzheimer's disease. Acta Neuropathol (1990) 1.28
Reactivity patterns and epitope specificities of anti-Cryptococcus neoformans monoclonal antibodies by enzyme-linked immunosorbent assay and dot enzyme assay. Infect Immun (1997) 1.27
Reactive nitrogen intermediates in human neuropathology: an overview. Dev Neurosci (1994) 1.27
Cryptococcus neoformans survive and replicate in human microglia. Lab Invest (1995) 1.26
Fungal morphogenesis and virulence. Med Mycol (2000) 1.26
Sterol composition of Cryptococcus neoformans in the presence and absence of fluconazole. Antimicrob Agents Chemother (1994) 1.26
Antibody response to Cryptococcus neoformans proteins in rodents and humans. Infect Immun (1999) 1.26
Melanization affects susceptibility of Cryptococcus neoformans to heat and cold. FEMS Microbiol Lett (1997) 1.26
Use of licensed vaccines for active immunization of the immunocompromised host. Clin Microbiol Rev (1998) 1.26
Genetic relationship between Cryptococcus neoformans var. neoformans strains of serotypes A and D. J Clin Microbiol (1998) 1.26
Sterol compositions and susceptibilities to amphotericin B of environmental Cryptococcus neoformans isolates are changed by murine passage. Antimicrob Agents Chemother (1995) 1.24
Serum cryptococcal antigen in patients with AIDS. Clin Infect Dis (1996) 1.24
False-negative cerebrospinal fluid cryptococcal latex agglutination tests for patients with culture-positive cryptococcal meningitis. J Clin Microbiol (1993) 1.24
Evaluation of acute hematologic and long-term pulmonary toxicities of radioimmunotherapy of Cryptococcus neoformans infection in murine models. Antimicrob Agents Chemother (2004) 1.24
Evidence that Cryptococcus neoformans is melanized in pigeon excreta: implications for pathogenesis. Infect Immun (1999) 1.23
Antigen-induced protective and nonprotective cell-mediated immune components against Cryptococcus neoformans. Infect Immun (1998) 1.23